★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Stevanato Group S.p.A. (STVN) Moat Analysis
Stevanato Group S.p.A.
STVN · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Stevanato Group supplies injectable-drug packaging, delivery systems and pharmaceutical production equipment. Q2 2026 revenue was 45.01% High-Value Solutions, 43.14% other containment and delivery, and 11.85% Engineering. High-value packaging has two defensible mechanisms: drug-file qualification/design-in and proprietary process/capacity know-how; reputation and claimed EZ-Fill standard status are supporting evidence rather than separate moats. Standard containment retains only weaker qualification friction; ordinary multi-year contracts are not independently protective. Engineering is verified moatless because after-sales availability is not evidence of proprietary lock-in and Q2 operating margin was 2.9%. Recalculated June 2026 TTM margins are 29.17% gross, 16.37% operating and 10.99% net. At June 30, 302,842,536 shares were issued: 49,832,201 NYSE-listed ordinary shares and 253,010,335 multiple-vote Class A shares, with 29,716,359 Class A shares in treasury, leaving 273,126,177 economic shares outstanding.
Primary segment
High-Value Solutions
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 7 tags
Updated 2026-08-23
Segments
High-Value Solutions
High-value primary packaging and integrated solutions for injectable drugs
Revenue
45%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Other Containment and Delivery Solutions
Standard primary packaging and related services for injectable drugs and diagnostics
Revenue
43.1%
Structure
Competitive
Pricing
weak
Share
—
Peers
Engineering
Pharmaceutical production, inspection, assembly, packaging/serialization and glass converting equipment
Revenue
11.8%
Structure
Competitive
Pricing
weak
Share
—
Peers
—
Moat Claims
High-Value Solutions
High-value primary packaging and integrated solutions for injectable drugs
Revenue_share uses Q2 2026 revenue of EUR 135.930m over EUR 302.003m consolidated revenue. High-value revenue rose 16.4% year over year and represented 51% of BDS revenue. BDS gross margin was 31.1%, but profitability is not disclosed separately for high-value products. Glass-tube suppliers include Schott, NEG, Nipro, and Corning.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Primary packaging is part of the drug product and regulatory filing, so supplier changes require requalification; a Q2 regulatory approval incorporating both Alina and Stevanato cartridges demonstrates current design-in rather than a merely theoretical barrier.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Dual-sourcing reduces lock-in
- Competing container formats/materials (polymer, alternative delivery)
- Major customers use purchasing leverage
Leading indicators
- Share of customer programs using Stevanato RTU formats
- Churn/qualification losses on new molecule wins
- Gross margin and price/mix in high-value portfolio
Counterarguments
- Large pharma can and does qualify multiple suppliers
- Competitors can replicate performance features with enough time and capex
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
High-value products use proprietary manufacturing processes and command disclosed premium pricing. Q2 high-value revenue growth of 16% supports differentiated demand, but capable glass-packaging rivals and costly plant ramps limit the strength score.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Competitor capacity additions narrow supply tightness
- Process innovations diffuse over time
- Execution risk in ramping new plants/lines
Leading indicators
- Yield/scrap and customer complaint rates
- On-time delivery and capacity utilization at new sites
- R&D output (new platforms) and adoption
Counterarguments
- Large competitors can invest comparable capex and hire expertise
- Customer specs may standardize, reducing differentiation
Other Containment and Delivery Solutions
Standard primary packaging and related services for injectable drugs and diagnostics
Revenue_share uses Q2 2026 revenue of EUR 130.291m over EUR 302.003m consolidated revenue. Revenue rose 2.8% year over year, partly from variable compensation tied to one customer contract. Multi-year contracts support visibility but lack disclosed exclusivity or punitive switching terms, so they are not scored separately from qualification friction.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Even for more standard components, regulatory filings and qualification create switching friction and favor incumbent suppliers.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Standard components commoditize
- Customers qualify multiple suppliers
Leading indicators
- Customer concentration and multi-sourcing trends
- Pricing vs raw material inflation pass-through
Counterarguments
- Commodity products are easier to dual-source than specialized platforms
Engineering
Pharmaceutical production, inspection, assembly, packaging/serialization and glass converting equipment
Revenue_share uses Q2 2026 external revenue of EUR 35.782m over EUR 302.003m consolidated revenue. Revenue declined 2% year over year while after-sales and assembly growth offset weaker glass-converting and visual-inspection sales. Spare parts and maintenance exist, but no service mix, attach rate, proprietary lock-in or superior segment economics establishes an installed-base moat.
Evidence
included as part of the regulatory filings required before commercialization
Regulatory integration raises switching costs and extends qualification cycles.
changing providers can be a lengthy process
Company describes time costs to change providers, supporting qualification-driven stickiness.
This important customer project also embeds our world-class cartridge technology into the Alina® pen platform
A customer regulatory approval shows Stevanato components and delivery technology designed into a commercial therapy.
unique set of proprietary manufacturing processes
Signals process know-how and manufacturing capability as a barrier to entry.
we enjoy premium pricing
Premium pricing is consistent with differentiated products supported by know-how/capex.
Risks & Indicators
Erosion risks
- Dual-sourcing reduces lock-in
- Competing container formats/materials (polymer, alternative delivery)
- Major customers use purchasing leverage
- Competitor capacity additions narrow supply tightness
- Process innovations diffuse over time
- Execution risk in ramping new plants/lines
Leading indicators
- Share of customer programs using Stevanato RTU formats
- Churn/qualification losses on new molecule wins
- Gross margin and price/mix in high-value portfolio
- Yield/scrap and customer complaint rates
- On-time delivery and capacity utilization at new sites
- R&D output (new platforms) and adoption
Research STVN elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.